Bharat Biotech finds Covaxin 81% efficient in Phase 3 trials

Bharat Biotech's vaccine, whose emergency use approval before finishing final stage testing had triggered a row, has shown an 81 per cent efficacy in preventing symptomatic COVID-19 in an interim......

Lower input costs may aid pharma firms' Q2 margins

Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and......